Chimerix Inc. scrapped testing of its experimental antiviral in Ebola patients in Liberia, saying the number of infections had dropped in recent weeks, and that only a handful of patients had been enrolled in the Liberian study.
via WSJ.com: US Business http://ift.tt/1BKf7jc
via WSJ.com: US Business http://ift.tt/1BKf7jc
Nessun commento:
Posta un commento